Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision after the recent Q1. | April 21, 2023
Hansa Biopharma announced that the Italian Medicine Agency has granted full access and reimbursement for the use of Idefirix, the company s first-in-class treatment, for the desensitization of highly. | December 8, 2022